Processa Pharmaceuticals to Present PCS499 Study at ASN Kidney Week 2025
ByAinvest
Wednesday, Nov 5, 2025 9:17 am ET1min read
PCSA--
Processa Pharmaceuticals announced a poster presentation of its adaptive Phase 2/3 PCS499 study in FSGS at ASN Kidney Week 2025. PCS499 is an analog of pentoxifylline, which has shown potential in decreasing proteinuria in CKD patients. The study aims to optimize dosing and accelerate regulatory approval. The adaptive Phase 2/3 design is a critical step in addressing the urgent need for safer, more effective therapies for FSGS patients.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet